From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells

International Journal of Oncology

Volumn 43, Issue 4, 2013, Pages 1125-1130

  Liu, Tiancheng ^a   Mendes, Desiree E ^a   Berkman, Clifford E ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Androgen deprivation; Androgen receptor; C Met; Prostate cancer; Prostate specific membrane antigen

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; SCATTER FACTOR RECEPTOR;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LONG TERM CARE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

ANDROGENS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, ANDROGEN; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84882379339     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2020     Document Type: Article

References (26)

1. Gustavsson H, Welen K and Damber JE: Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis. Prostate 62: 364-373, 2005.
2. Niu Y, Altuwaijri S, Lai KP, et al: Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc Natl Acad Sci USA 105: 12182-12187, 2008.
3. Lee SO, Dutt SS, Nadiminty N, Pinder E, Liao H and Gao AC: Development of an androgen-deprivation induced and androgen suppressed human prostate cancer cell line. Prostate 67: 1293-1300, 2007.
4. Saraon P, Jarvi K and Diamandis EP: Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem 57: 1366-1375, 2011.
5. Devlin HL and Mudryj M: Progression of prostate cancer: multiple pathways to androgen independence. Cancer Lett 274: 177-186, 2009.
6. Watson PA, Chen YF, Balbas MD, et al: Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 107: 16759-16765, 2010.
7. Hendriksen PJ, Dits NF, Kokame K, et al: Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66: 5012-5020, 2006.
8. Lorenzo GD, Bianco R, Tortora G and Ciardiello F: Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin Prostate Cancer 2: 50-57, 2003.
9. Maeda A, Nakashiro K, Hara S, et al: Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophys Res Commun 347: 1158-1165, 2006.
10. Nishida S, Hirohashi Y, Torigoe T, et al: Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci 104: 431-436, 2013.
11. Matsumoto K and Nakamura T: Emerging multipotent aspects of hepatocyte growth factor. J Biochem 119: 591-600, 1996.
12. Verras M, Lee J, Xue H, Li TH, Wang Y and Sun Z: The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 67: 967-975, 2007.
13. Christensen JG, Burrows J and Salgia R: c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett 225: 1-26, 2005.
14. Gherardi E, Birchmeier W, Birchmeier C and Vande Woude G: Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12: 89-103, 2012.
15. Peruzzi B and Bottaro DP: Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 12: 3657-3660, 2006.
16. Liu T, Wu LY, Fulton MD, Johnson JM and Berkman CE: Prolonged androgen deprivation leads to downregulation of androgen receptor and prostate-specific membrane antigen in prostate cancer cells. Int J Oncol 41: 2087-2092, 2012.
17. Liu T, Wu LY, Hopkins MR, Choi JK and Berkman CE: A targeted low molecular weight near-infrared fluorescent probe for prostate cancer. Bioorg Med Chem Lett 20: 7124-7126, 2010.
18. Matroule JY, Carthy CM, Granville DJ, Jolois O, Hunt DW and Piette J: Mechanism of colon cancer cell apoptosis mediated by pyropheophorbide-a methylester photosensitization. Oncogene 20: 4070-4084, 2001.
19. Liu T, Wu LY and Berkman CE: Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption. Cancer Lett 296: 106-112, 2010.
20. Liu T, Toriyabe Y and Berkman CE: Purification of prostate specific membrane antigen using conformational epitope-specific antibody-affinity chromatography. Protein Expr Purif 49: 251-255, 2006.
21. Wolf DA, Herzinger T, Hermeking H, Blaschke D and Horz W: Transcriptional and posttranscriptional regulation of human androgen receptor expression by androgen. Mol Endocrinol 7: 924-936, 1993.
22. Hu P, Chu GC, Zhu G, et al: Multiplexed quantum dot labeling of activated c-Met signaling in castration-resistant human prostate cancer. PLoS One 6: e28670, 2011.
23. Suzuki H, Ueda T, Ichikawa T and Ito H: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10: 209-216, 2003.
24. Smith DC, Smith MR, Sweeney C, et al: Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 31: 412-419, 2013.
25. Humphrey PA, Zhu X, Zarnegar R, et al: Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 147: 386-396, 1995.
26. Colombel M, Eaton CL, Hamdy F, et al: Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate 72: 713-720, 2012.